202 related articles for article (PubMed ID: 35541904)
1. The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth.
Zhang Y; Cheng L; Shi X; Song Y; Chen XY; Chen MB; Yao J; Zhang ZQ; Cai S
Int J Biol Sci; 2022; 18(7):2994-3005. PubMed ID: 35541904
[TBL] [Abstract][Full Text] [Related]
2. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
[TBL] [Abstract][Full Text] [Related]
3. Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth.
Jin L; Zhu J; Yao L; Shen G; Xue BX; Tao W
Cell Death Dis; 2023 Aug; 14(8):537. PubMed ID: 37604912
[TBL] [Abstract][Full Text] [Related]
4. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V.
Sun X; Shan HJ; Yin G; Zhang XY; Huang YM; Li HJ
Cell Death Discov; 2022 Feb; 8(1):48. PubMed ID: 35115496
[TBL] [Abstract][Full Text] [Related]
5. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
6. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
Chen L; Wang L; Han Z; Qin P; Niu G; Du J
Tohoku J Exp Med; 2024 Mar; 262(3):173-180. PubMed ID: 38123304
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells.
Yang YL; Ji C; Cheng L; He L; Lu CC; Wang R; Bi ZG
Cancer Sci; 2012 Aug; 103(8):1538-45. PubMed ID: 22594559
[TBL] [Abstract][Full Text] [Related]
8. Activation of SphK1 by K6PC-5 Inhibits Oxygen-Glucose Deprivation/Reoxygenation-Induced Myocardial Cell Death.
Shao JJ; Peng Y; Wang LM; Wang JK; Chen X
DNA Cell Biol; 2015 Nov; 34(11):669-76. PubMed ID: 26308910
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation.
Nemoto S; Nakamura M; Osawa Y; Kono S; Itoh Y; Okano Y; Murate T; Hara A; Ueda H; Nozawa Y; Banno Y
J Biol Chem; 2009 Apr; 284(16):10422-32. PubMed ID: 19240026
[TBL] [Abstract][Full Text] [Related]
10. Targeting sphingosine kinase-1 to inhibit melanoma.
Madhunapantula SV; Hengst J; Gowda R; Fox TE; Yun JK; Robertson GP
Pigment Cell Melanoma Res; 2012 Mar; 25(2):259-74. PubMed ID: 22236408
[TBL] [Abstract][Full Text] [Related]
11. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.
Kim HS; Yoon G; Ryu JY; Cho YJ; Choi JJ; Lee YY; Kim TJ; Choi CH; Song SY; Kim BG; Bae DS; Lee JW
Oncotarget; 2015 Sep; 6(29):26746-56. PubMed ID: 26311741
[TBL] [Abstract][Full Text] [Related]
13. Hispidulin mediates apoptosis in human renal cell carcinoma by inducing ceramide accumulation.
Gao H; Gao MQ; Peng JJ; Han M; Liu KL; Han YT
Acta Pharmacol Sin; 2017 Dec; 38(12):1618-1631. PubMed ID: 29119970
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.
Song L; Xiong H; Li J; Liao W; Wang L; Wu J; Li M
Clin Cancer Res; 2011 Apr; 17(7):1839-49. PubMed ID: 21325072
[TBL] [Abstract][Full Text] [Related]
16. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
Zhang D; Xia H; Zhang W; Fang B
Tumour Biol; 2016 Jan; 37(1):1327-36. PubMed ID: 26293898
[TBL] [Abstract][Full Text] [Related]
17. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo.
Yang L; Weng W; Sun ZX; Fu XJ; Ma J; Zhuang WF
Biochem Biophys Res Commun; 2015 May; 460(4):903-8. PubMed ID: 25824043
[TBL] [Abstract][Full Text] [Related]
18. K6PC-5, a novel sphingosine kinase 1 (SphK1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating SphK1-Akt signaling.
Ji F; Mao L; Liu Y; Cao X; Xie Y; Wang S; Fei H
Biochem Biophys Res Commun; 2015 Mar; 458(3):568-575. PubMed ID: 25680461
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
20. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]